#Evusheld2 news:
First person dosed for trial.

Let's hope it is effective against new variants 🫰.

RT @SGriffin_Lab@twitter.com

Prophylactic therapy for #CEV and the immunocompromised can be a real game changer.
Companies, governments, and regulators need to recognise this and follow the example of @AstraZeneca@twitter.com

@drlennardlee@twitter.com
@AlexRichter3@twitter.com
@cv_cev@twitter.com
https://www.astrazeneca-us.com/media/statements/2022/first-participant-dosed-in-supernova-phase-I-III-trial-evaluating-azd5156-a-next-generation-long-acting-antibody-combination-for-prevention-of-covid-19.html

🐦🔗: https://twitter.com/SGriffin_Lab/status/1608386386612158465

Trial on #Evusheld2 in the US🇺🇸 for age 12yrs+ (NB/ not recruiting yet):

https://clinicaltrials.gov/ct2/show/NCT05648110

RT @IreneBlancoMD@twitter.com

Finally sitting with @alhkim@twitter.com after his fantastic talk on #COVID in #immunocompromised patients. Highest risk groups are those on Rituxan followed my mycophenolate then steroids! Get your vaccines everyone and pray for #Evusheld2.0!

🐦🔗: https://twitter.com/IreneBlancoMD/status/1600343174395797504